The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.

Source: CancerNetwork - September 18, 2018 Category: Cancer & Oncology Authors: James J. Lee, MD, PhD, Edward Chu, MD Source Type: news